Δ9-THCP acetate (Δ9-Tetrahydrocannabiphorol acetate) is structurally similar to known phytocannabinoids.

Δ9-THCBA-A (Δ9-Tetrahydrocannabinolic acid-C4) is structurally similar to known phytocannabinoids.

Δ9-Tetrahydrocannabiorcol is structurally similar to known phytocannabinoids.

Δ8-THCPA-A (Δ8-Tetrahydrocannabiphorolic acid) is structurally similar to known phytocannabinoids.

Δ8-THCP (Δ8-Tetrahydrocannabiphorol; n-Heptyl Δ8-THC) (Compound 1a) is a semisynthetic cannabinoid that serves as an analytical reference standard and exhibits affinity for the CB1 receptor.

Δ8-THC-ethyl (Ethyl-Δ8-Tetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Δ8-THCBA-A (Δ8-Tetrahydrocannabibutolic acid A) is structurally similar to known phytocannabinoids.

Δ8-THCB (∆8-Tetrahydrocannabutol) is a structural analog of phytocannabinoids. Δ8-THCB is also an analog of Δ8-tetrahydrocannabinol.

Δ8-THC methyl ether (compound 3) shows a good docking score (-10.167 kcal/mol) for CB2 receptor. Δ8-THC methyl ether has antinociceptive activity in mice.

Δ8-THC Glucuronide is a phytocannabinoid metabolite.

Δ8-Tetrahydrocannabivarin is a cannabinoid.

Δ8-iso-THC is structurally similar to known phytocannabinoids.

Δ4-Iso-THC (Δ4-Iso-tetrahydrocannabinol) is a cannabidiol derivative with potential cytotoxicity targeting cancer cells.

Δ4(8)-iso-THC (Δ4(8)-Isotetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism.

Rezosicone is the antagonist for cannabinoid CB1 receptor.

PTI-1 is a synthetic cannabinoid (CB) that contains the 1-pentyl-indole structure.

ortho-CBNQ (o-Cannabinolquinone) is an oxidative byproduct of Cannabidiol.

O-2545 hydrochloride is a highly potent, water-soluble CB1/CB2 receptor agonist (with Ki values of 1.5 and 0.32 nM for CB1 and CB2 respectively), can be used for epilepsy, pain, multiple sclerosis research.

NAPIE is structurally similar to known synthetic cannabinoids.

MEP-FUBICA is structurally categorized as a synthetic cannabinoid.

MDMB-FUBICA metabolite 3 is structurally classified as a synthetic cannabinoid. MDMB-FUBICA metabolite 3 is a metabolite of MDMB-FUBICA.

MDMB-FUBICA, a synthetic cannabinoid, is a potent agonist of the cannabinoid receptors with psychoactive properties. MDMB-FUBICA can be used in electronic cigarette.

MDMB-FUB7AICA is structurally similar to known synthetic cannabinoids.

MDA77 is a CB2 inverse agonist with an EC50 of 5.82 nM, showing selectivity for human CB2 and no activity on CB1.

MDA7 is the selective agonist for cannabinoid receptor 2 with EC50 of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with Ki of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models.

iso-Hexahydrocannabinol is structurally similar to known phytocannabinoids.

Hexocannabitriol is structurally similar to known phytocannabinoids.

FDU-PB-22 is a new synthetic cannabinoid that is rapidly metabolized in HLM, with a half-life of 12.4 minutes.

exo-THCP (exo-Tetrahydrocannabiphorol) is structurally similar to known phytocannabinoids.